My Video Playlist »
Empty Playlist
|
|
|
Litigation involving drug maker Merck has revealed new information about safety concerns associated with the drug Vioxx, pull...
Litigation involving drug maker Merck has revealed new information about safety concerns associated with the drug Vioxx, pulled from the market in 2004. Legal documents recently...
0
|
Litigation involving drug maker Merck has revealed new information about safety concerns associated with the drug Vioxx, pull... |
|
|
|
|
|
|
A Texas appeals court has overturned a verdict against drugmaker Merck in a case involving its withdrawn painkiller Vioxx. AP...
A Texas appeals court has overturned a verdict against drugmaker Merck in a case involving its withdrawn painkiller Vioxx. AP's Mark Hamrick reports on that and the rest of...
0
|
A Texas appeals court has overturned a verdict against drugmaker Merck in a case involving its withdrawn painkiller Vioxx. AP... |
|
|
|
|
|
|
Tailored Therapy - Increase Efficacy of Cetuximab
Tailored Therapy - Increase Efficacy of Cetuximab
1
|
Tailored Therapy - Increase Efficacy of Cetuximab |
|
|
|
|
|
|
Adel Mahmoud M.D., Senior Policy Analyst and Lecturer with the rank of Professor at the Woodrow Wilson School and the Univers...
Adel Mahmoud M.D., Senior Policy Analyst and Lecturer with the rank of Professor at the Woodrow Wilson School and the University`s Department of Molecular Biology, and former...
0
|
Adel Mahmoud M.D., Senior Policy Analyst and Lecturer with the rank of Professor at the Woodrow Wilson School and the Univers... |
|
|
|
|
|
|
In this jobcast we'll talk Annette Orella, a Project Director in the Merck Manufacturing development program. She'll explain ...
In this jobcast we'll talk Annette Orella, a Project Director in the Merck Manufacturing development program. She'll explain their hiring needs in the Merck Manufacturing...
0
|
In this jobcast we'll talk Annette Orella, a Project Director in the Merck Manufacturing development program. She'll explain ... |
|
|
|
|
|
|
A necessary evil? Please rate, comment and pass on to your friends and associates. If you disagree with my message, please fe...
A necessary evil? Please rate, comment and pass on to your friends and associates. If you disagree with my message, please feel free to say so. lets get the conversation started....
0
|
A necessary evil? Please rate, comment and pass on to your friends and associates. If you disagree with my message, please fe... |
|
|
|
|
|
|
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, sha...
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.
0
|
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, sha... |
|
|
|
|
|
|
They Just Don't Get Merck or Schering!
They Just Don't Get Merck or Schering!
0
|
They Just Don't Get Merck or Schering! |
|
|
|
|
|
|
For their next several jobcasts well be profiling various Merck military veterans about their experience as they transition f...
For their next several jobcasts well be profiling various Merck military veterans about their experience as they transition from military to civilian life while working for one of...
0
|
For their next several jobcasts well be profiling various Merck military veterans about their experience as they transition f... |
|
|
|
|
|
|
U.S. stocks rallied back after steep losses seen at the end of last week as $23.5 billion in new deals and stronger-than-expe...
U.S. stocks rallied back after steep losses seen at the end of last week as $23.5 billion in new deals and stronger-than-expected results from Merck gave the bulls a boost.
0
|
U.S. stocks rallied back after steep losses seen at the end of last week as $23.5 billion in new deals and stronger-than-expe... |
|
|
|
|
|
